A second wind for the cholinergic system in Alzheimer's therapy

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• The cholinergic hypothesis, proposed 35 years ago, identified acetylcholine depletion as a primary cause of cognitive decline in Alzheimer's disease (AD).
• This hypothesis drove the development of anticholinesterase inhibitor therapies, the main AD treatments despite limited efficacy.
• Current research revives the cholinergic hypothesis with new evidence from animal models and human imaging.

Purpose of the Study:

• To review the historical and current evidence supporting the cholinergic hypothesis of Alzheimer's disease.
• To discuss the implications of early cholinergic dysfunctions and compensatory mechanisms in AD pathogenesis.
• To explore new therapeutic strategies and early diagnostic biomarkers for AD based on cholinergic system research.

Main Methods:

• Review of historical studies on cholinergic function in aging and AD.
• Analysis of recent findings from novel animal models of AD.
• Examination of advanced human neuroimaging techniques to assess cholinergic system activity.

Main Results:

• Cholinergic dysfunctions are detected earlier in AD development than previously thought.
• The brain exhibits compensatory mechanisms involving the cholinergic system to delay AD progression.
• Anticholinesterase inhibitors, while partially effective, represent the primary therapeutic approach.

Conclusions:

• The cholinergic hypothesis remains relevant, with new insights into early detection and disease mechanisms.
• Understanding cholinergic system alterations and compensatory responses is crucial for developing effective AD multitherapies.
• Early diagnosis through biomarkers and targeted cholinergic interventions are vital for combating AD, which begins in early adulthood.